Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.79M | $12.7M | $9.54M | $3.57M | $7.42M | $4.65M | $2.36M | $6.88M | $7.02M | $1.54M |
| Revenue growth | — | 87.8% | -25.2% | -62.5% | 107.6% | -37.3% | -49.3% | 192.0% | 2.0% | -78.0% |
| Operating income | -$133M | -$122M | -$156M | -$55.0M | -$63.4M | -$71.2M | -$115M | -$155M | -$195M | -$287M |
| Operating margin | -1958.7% | -953.7% | -1640.1% | -1540.2% | -854.1% | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -18599.8% |
| Net income | — | — | — | — | — | — | — | -$141M | -$158M | -$259M |
| Net margin | — | — | — | — | — | — | — | -2054.8% | -2248.8% | -16748.0% |
| EPS (diluted) | -$18.99 | -$10.86 | -$14.48 | -$3.51 | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$113M | -$99.9M | -$75.2M | -$46.4M | -$40.4M | -$60.9M | -$104M | -$107M | -$158M | -$211M |
| Capital expenditures | $2.75M | $1.79M | $813K | $731K | $1.55M | $1.25M | $1.83M | $1.82M | $1.92M | $2.71M |
| Free cash flow | -$116M | -$102M | -$76.0M | -$47.1M | -$42.0M | -$62.2M | -$106M | -$109M | -$160M | -$214M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $42.5M | $40.3M | $24.3M | $11.2M | $43.8M | $39.1M | $29.4M | $34.8M | $28.4M | $28.9M |
| Total assets | $383M | $316M | $156M | $123M | $236M | $445M | $353M | $466M | $792M | $583M |
| Total liabilities | $118M | $79.3M | $31.7M | $28.9M | $26.5M | $25.2M | $26.5M | $36.5M | $45.3M | $55.8M |
| Shareholders' equity | $265M | $236M | $124M | $94.0M | $209M | $419M | $326M | $429M | $747M | $527M |
| Retained earnings | -$719M | -$813M | -$962M | -$1.01B | -$1.07B | -$1.14B | -$1.26B | -$1.40B | -$1.56B | -$1.81B |
| Shares (wtd avg diluted) | 121M | 9.23M | 12.0M | 14.5B | 29.6B | 42.9B | 46.9B | 48.4M | 64.4M | 66.4M |
Every figure is extracted from Celldex Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.